Clinical and organisational aspects of haemophilia care: the patients' view.
作者信息
Calizzani Gabriele, Arcieri Romano
出版信息
Blood Transfus. 2012 Jan;10(1):110-1. doi: 10.2450/2011.0043-11. Epub 2011 Sep 21.
Abstract
摘要
相似文献
1
Clinical and organisational aspects of haemophilia care: the patients' view.血友病护理的临床与组织方面：患者视角
Blood Transfus. 2012 Jan;10(1):110-1. doi: 10.2450/2011.0043-11. Epub 2011 Sep 21.
2
Factor VIII inhibitor and source of replacement therapy.凝血因子 VIII 抑制剂及替代疗法的来源。
Blood Transfus. 2012 Jan;10(1):112-3. doi: 10.2450/2011.0064-11. Epub 2011 Sep 21.
3
Blood safety and the choice of anti-hemophilic factor concentrate.
Pediatr Blood Cancer. 2007 Jan;48(1):117. doi: 10.1002/pbc.21086.
4
New-variant Creutzfeldt-Jakob disease and treatment of haemophilia. Executive Committee of the UKHCDO. United Kingdom Haemophilia Centre Directors' Organisation.
Lancet. 1997 Dec 6;350(9092):1704. doi: 10.1016/s0140-6736(05)64307-3.
5
[Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].[病毒灭活的凝血因子VIII和IX浓缩物在血友病治疗中的病毒安全性现状]
Infusionsther Transfusionsmed. 1994 Aug;21 Suppl 1:80-3.
6
[Safety in hemophilia A treatment. Viral inactivation of FVIII:C concentrates].[甲型血友病治疗中的安全性。FVIII:C 浓缩剂的病毒灭活]
Acta Med Port. 1992 Dec;5(11):587-90.
7
[Treatment with plasma concentrates in hemophilia A. State Security and Health Planning Office. Expert Panel].[甲型血友病的血浆浓缩物治疗。国家安全与健康规划办公室。专家小组]
Sangre (Barc). 1994 Apr;39(2):157-61.
8
[Virus in hemophilia: current status and future perspectives].[血友病中的病毒：现状与未来展望]
Sangre (Barc). 1996 Apr;41(2):141-5.
9
In vivo recovery and safety of human factor VIII product AAFACT in patients with haemophilia A.人凝血因子VIII产品AAFACT在A型血友病患者体内的回收率及安全性
Haemophilia. 2003 Mar;9(2):157-63. doi: 10.1046/j.1365-2516.2003.00730.x.
10
Viral safety issues: plasma-derived factor VIII.病毒安全性问题：血浆源性凝血因子VIII。
Ann Hematol. 1994;68 Suppl 3:S35-6. doi: 10.1007/BF01774528.
引用本文的文献
1
Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy.意大利血友病及先天性出血性疾病的治疗原则与管理建议更新
Blood Transfus. 2014 Oct;12(4):575-98. doi: 10.2450/2014.0223-14.
2
Uncovered needs in the management of inherited bleeding disorders in Italy.意大利遗传性出血性疾病管理中未被满足的需求。
Blood Transfus. 2014 Apr;12 Suppl 3(Suppl 3):s563-6. doi: 10.2450/2014.0036-14s.
3
Present and future challenges in the treatment of haemophilia: the patient's perspective.血友病治疗中的当前与未来挑战：患者视角
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s82-5. doi: 10.2450/2013.013s.
4
The demand for factor VIII and for factor IX and the toll fractionation product surplus management.对凝血因子 VIII、凝血因子 IX 的需求以及凝血因子浓缩物产品过剩管理。
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s64-76. doi: 10.2450/2013.011s.
5
Plasma and plasma-derived medicinal product self-sufficiency: the Italian case.血浆及血浆衍生药品的自给自足：意大利的情况
Blood Transfus. 2013 Sep;11 Suppl 4(Suppl 4):s118-31. doi: 10.2450/2013.018s.
6
Factor VIII inhibitor and source of replacement therapy.凝血因子 VIII 抑制剂及替代疗法的来源。
Blood Transfus. 2012 Jan;10(1):112-3. doi: 10.2450/2011.0064-11. Epub 2011 Sep 21.
本文引用的文献
1
Factor VIII safety: plasma-derived versus recombinant products.凝血因子VIII的安全性：血浆源性产品与重组产品
Blood Transfus. 2011 Oct;9(4):366-70. doi: 10.2450/2011.0092-10. Epub 2011 Apr 12.
2
Plasma-derived versus recombinant Factor VIII concentrates for the treatment of haemophilia A: recombinant is better.用于治疗甲型血友病的血浆源性与重组凝血因子 VIII 浓缩剂：重组的更好。
Blood Transfus. 2010 Oct;8(4):292-6. doi: 10.2450/2010.0067-10.
3
Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasma-derived is better.用于治疗甲型血友病的血浆源性与重组凝血因子VIII浓缩剂：血浆源性的更好。
Blood Transfus. 2010 Oct;8(4):288-91. doi: 10.2450/2010.0072-10.
4
Mortality and causes of death in Italian persons with haemophilia, 1990-2007.意大利血友病患者 1990-2007 年的死亡率和死因。
Haemophilia. 2010 May;16(3):437-46. doi: 10.1111/j.1365-2516.2009.02188.x. Epub 2010 Feb 9.
5
European principles of haemophilia care.欧洲血友病护理原则。
Haemophilia. 2008 Mar;14(2):361-74. doi: 10.1111/j.1365-2516.2007.01625.x. Epub 2008 Jan 30.
Zotero 插件